+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A six months follow-up randomized controlled trial of lamivudine combined with zidovudine vs lamivudine plus zidovudine plus zalcitabine or didanosine in HIV-1 infection and CD4+ cell count between 50-300/mu-L



A six months follow-up randomized controlled trial of lamivudine combined with zidovudine vs lamivudine plus zidovudine plus zalcitabine or didanosine in HIV-1 infection and CD4+ cell count between 50-300/mu-L



Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 36: 206




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 029791790

Download citation: RISBibTeXText


Related references

Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. Annals of Internal Medicine 125(3): 161-172, 1996

A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. Journal of Acquired Immune Deficiency Syndromes 27(2): 116-123, 2001

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 276(2): 111-117, 1996

Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine. Aids Research and Human Retroviruses 16(14): 1337-1344, 2000

Evolution of HIV drug resistance in zidovudine/zalcitabine- and zidovudine/didanosine-experienced patients receiving lamivudine-containing combination therapy. Antiviral Therapy 3(2): 81-88, 1998

Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. AIDS 13(6): 685-694, 1999

Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Clinical Infectious Diseases 47(8): 1083-1092, 2008

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 285(9): 1155-1163, 2001

Abacavir, Didanosine and Stavudine versus Ritonavir, Saquinavir, Zidovudine and Lamivudine or Nelfinavir, Nevirapine, Zidovudine and Lamivudine in antiretroviral naive HIV patients. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 42: 261, 2002

Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antiviral Therapy 8(2): 163-171, 2003

Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection. Aids Research and Human Retroviruses 17(3): 203-210, 2001

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). Aids Research and Therapy 6: 3, 2009

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 276(2): 118-125, 1996

AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients. Antiviral Therapy 6(2): 127-134, 2001

AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. Aids 14(4): 367-374, 2000